Delivery Order SPE2DB20D2104-SPE2DB23FS01S
- Not listed
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,328.22 delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose treatment medication. The award is part of a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999 that Amerisourcebergen's parent company, Cencora, Inc., holds with the DLA Troop Support Medical....
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,449.12 firm fixed-price delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The contract has an ultimate completion date of December 20, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- This federal contract award, valued at $1,044.34, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a large pharmaceutical distribution company. The award is a delivery order for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. The contract does not have a set-aside designation, indicating it was awarded on a full and open competition basis. Amerisourcebergen holds a significant Indefinite Delivery Contract (IDC) with the...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,289.62 firm-fixed-price delivery order is for NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to prevent opioid overdose. The contract has a period of performance through February 21, 2023. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation. The $1,662.48 firm fixed price delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical opioid overdose reversal medication. The contract is not designated as a set-aside and is part of a larger indefinite delivery contract (IDC) awarded solely to Amerisourcebergen Drug Corp,...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,986.84 firm fixed-price delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,641.63 Firm Fixed Price Delivery Order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The contract has an ultimate completion date of January 3, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop...
- This federal contract award, valued at $17,982.89, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used for opioid overdose reversal. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,400.64 fixed-price delivery order is for the supply of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdoses. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a comprehensive...
- This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,914.32 firm fixed-price delivery order is for the provision of NARCAN 4 MG NASAL SPRAY 2S, a critical medication used to treat opioid overdose. The contract has an ultimate completion date of August 28, 2024. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
- SPE2DB20D2104Indefinite Delivery Contract
- SPE2DB20D2104-SPE2DB23FS01SDelivery Order
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $4,210.68 firm-fixed-price delivery order is for the supply of NARCAN 4 MG Nasal Spray, a critical medication used for opioid overdose reversal. The award is associated with a larger Indefinite Delivery Contract (IDC) valued at up to $999,999,999.00 that AmerisourceBergen holds with the DLA Troop Support Medical. This IDC serves as the primary vehicle for the company to deliver a comprehensive range of pharmaceutical products and medical supplies to DLA facilities supporting the Department of Defense worldwide. The contract does not have a set-aside designation, indicating open competition. In addition to the DLA contract, AmerisourceBergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at up to $750,000, for similar medical products and prescription drugs. These IDCs demonstrate the company's capacity to meet the diverse and critical pharmaceutical needs of multiple government agencies on a large scale.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 1/31/23 |